US/UK/Canada

Share

Pick a time period -
Tags ( Active)

A historic year ended with a quarter of sales records

FOURTH QUARTER 2019 (OCT - DEC) ·  Net sales of non-durable goods in the quarter amounted to SEK 59.4 (52.3) million, corresponding to an increase of 14 percent in SEK and 6 percent in local currency. Total net sales (incl. durable goods) in the quarter amounted to SEK 62.4 (58.4) million, corresponding to an increase of 7 percent in SEK and 0 percent in local currency. · Net sales of non-durable goods in the quarter amounted to SEK 59.4 (52.3) million, corresponding to an increase of 14 percent in SEK and 6 percent in local currency. Total net sales (incl. durable goods) in the

Third XPS™ sold in Australia

The Fiona Stanley Hospital in Perth, Western Australia has recently acquired an XPS from XVIVO Perfusion AB (publ). This acquisition now sees three of the four Australian hospitals participating in the adult heart and lung transplant program having access to an XPS to assist in performing EVLP (Ex Vivo Lung Perfusion).  The Fiona Stanley Hospital XPS was kindly donated by Conquer Cystic Fibrosis Inc and the Spinnaker Health Research Foundation.XVIVO Perfusion has sold an XPS to Fiona Stanley Hospital in Perth, Western Australia. Together with The Prince Charles Hospital, Brisbane and The

Good growth and new important XPS clinics

THIRD QUARTER 2019 (JULY - SEPTEMBER) · Net sales of non-durable goods in the quarter amounted to SEK 50.1 (40.3) million, corresponding to an increase of 25 percent in SEK and 18 percent in local currency. Total net sales (incl. durable goods) in the quarter amounted to SEK 54.3 (40.9) million, corresponding to an increase of 33 percent in SEK and 26 percent in local currency. · Sales from warm perfusion represented 42 percent (40) of sales of non-durable goods. · Operating income before depreciation and amortization (EBITDA) adjusted for costs for a share-based bonus program

XVIVO has received market approval (PMA) from the FDA for STEEN Solution™ and XPS™

On April 26, 2019 XVIVO received Premarket approval (PMA) from the FDA for the products XPS™ and STEEN Solution™ for sale on the American market. The approval means that STEEN Solution™, XPS™ and the accompanying single-use articles are the only medical device products that are approved for Ex Vivo Lung Perfusion (EVLP) of initially unacceptable donated lungs at body temperature.Please see FDA press release on the following link: https://www.fda.gov/news-events/press-announcements/fda-approves-device-help-increase-access-more-lungs-transplant Just over 40 percent of all lung

PMA application for XPS™ with STEEN Solution™ submitted to the FDA

XVIVO Perfusion has submitted the PMA (Premarket Approval) application for the XPS™ with STEEN Solution™ to the FDA. The NOVEL Extension Clinical trial, that completed enrollment in 2017 constitutes the basis of the company’s PMA application.Lung transplantation remains a last treatment option for patients with end stage lung disease. Unfortunately, the lung is one of the least transplanted organs, leaving many patients with end stage lung disease to die without ever receiving a lung transplant. In 2016, 2322 patients received lung transplants in the US, 136 patients were removed from the

There are no items matching the current filter
There are no more items matching the current filter
Back to top